Disclosed herein are methods for overfilling primary packaging components, and drug products prepared according to those methods. The methods may include introducing a volume of a formulated drug substance into a primary packaging component having a nominal volume, where the volume of the formulated drug substance is greater than the nominal volume of the primary packaging component. In some cases, the primary packaging component may be a prefillable syringe.

The present invention relates to a microneedle, to a mould for producing same, and to a production method for same. More specifically, the present invention concerns a microneedle for causing a skin-beautifying substance or drug to be absorbed via the skin, to a plastic mould for producing same, and to a production method for same.

A nasal delivery device can include a nasal prong and an activation member. The nasal prong can have an opening at a top and bottom portion of the prong to allow for the passage of an aerosolized treatment agent through the nasal prong. The activation member can be positioned on the nasal delivery device at a location that is spaced apart from the subject's oral cavity when the nasal prong is received into the nostril of the subject. The activation member can detect a desired exhalation state of the subject and upon detection of the desired exhalation state, the activation member activates the delivery of the aerosolized treatment agent.

Embodiments of the invention provide multi-stage biodegradable drug delivery platforms and methods for the subcutaneous delivery of therapeutic agents (TA). Embodiments of the platform may be configured to subcutaneously deliver a first dose of a first TA which is absorbed into the body and/or blood stream (BBS) to produce a first therapeutic effect for a first selectable time period (STP), and subsequently after a second STP, deliver a second dose of a second TA which is absorbed into the BBS to produce a second therapeutic effect for a third STP. An embodiment of the platform may comprise a body having a tissue-penetrating end, a primary cavity having a first TA dose and a shell having a secondary cavity having a second TA dose. The first TA dose is released after the first STP and the second TA dose is released after the second STP by biodegradation of the shell.

A medicament injection device including a needle, a first stage that controls positioning of the needle at a depth into an animal when the device is pressed against the animal, and a second stage that injects the medicament through the needle into the animal after the needle is positioned at the depth and the device is further pressed against the animal. The device preferably includes a mechanism that permits the second stage to inject the medicament only after the needle is positioned at the depth. The depth of the needle preferably is adjustable, as is the amount of the medicament injected. In preferred aspects, these two features are independently adjustable. One or more springs, pneumatics elements, or other elements may automatically reset the first stage, the second stage, or both after the device is withdrawn from the animal. Also, associated methods.

The present disclosure provides a microneedle array for administering various drugs, a microneedle structure including the microneedle array, a method of fabricating the microneedle array, and a method of fabricating the microneedle structure. The microneedle array of the present disclosure includes a plurality of microneedles, the surfaces of which are coated with a liquid drug and a base for supporting the microneedles. According to the present disclosure, the microneedles are divided into two or more areas, and the surfaces of microneedles disposed in each of the divided areas are coated with different liquid drugs. In this case, the ingredient of a liquid drug coated on microneedles disposed in one of the divided areas is different from the ingredients of liquid drugs coated on microneedles disposed in the remainder of the divided areas.

The microneedle structure of the present disclosure includes a plurality of microneedle arrays, some of the surfaces of which are coated with a liquid drug and a body for supporting the microneedle arrays. According to the present disclosure, the microneedle arrays are coupled to the body so that the microneedle arrays are divided into two or more areas, and the microneedle arrays are coated with different liquid drugs. In this case, the ingredient of a liquid drug coated on at least one of the microneedle arrays is different from the ingredients of liquid drugs coated on the remainder of the microneedle arrays.

Embodiments of the invention provide multi-stage biodegradable drug delivery platforms and methods for the subcutaneous delivery of therapeutic agents (TA). Embodiments of the platform may be configured to subcutaneously deliver a first dose of a first TA which is absorbed into the body and/or blood stream (BBS) to produce a first therapeutic effect for a first selectable time period (STP), and subsequently after a second STP, deliver a second dose of a second TA which is absorbed into the BBS to produce a second therapeutic effect for a third STP. An embodiment of the platform may comprise a body having a tissue-penetrating end, a primary cavity having a first TA dose and a shell having a secondary cavity having a second TA dose. The first TA dose is released after the first STP and the second TA dose is released after the second STP by biodegradation of the shell.

Module for operational control of the guided advance/withdrawal device of the needle added to the smart substance injection device on board equipment for inoculating substances inside a fertile egg and smart method for injection inside a fertile egg, wherein the inoculation of substances inside a fertile egg, be this into the embryo, in the case of vaccines, and even into the amniotic fluid, in the case of a nutrient or nutritional vaccine complex, allows the injection needle (11) to be brought close at a controlled speed.

Disclosed herein are methods for overfilling primary packaging components, and drug products prepared according to those methods. The methods may include introducing a volume of a formulated drug substance into a primary packaging component having a nominal volume, where the volume of the formulated drug substance is greater than the nominal volume of the primary packaging component. In some cases, the primary packaging component may be a prefillable syringe.

The present invention provides a particulate delivery device with an automatic activation mechanism that pierces or cuts a composition capsule when a cap is removed. The cap cannot be replaced once the device is activated for use. The device allows for gas flow through the device from a gas inlet to a gas outlet through a composition receptacle and dispersion chamber to deliver particulate to the airway of a subject.